An observational study in Polycystic Ovary and Obesity, sponsored by Hatice Akkaya. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-06-26.
Sponsored by Hatice Akkaya · Observational
This is an original study giving an information about the association body mass index, polycystic ovary syndrome and betatrophin.
Introduction: Betatrophin is a protein hormone which has a significant role in glucose homeostasis and lipid metabolism. The aim of this study is to compare the levels of serum betatrophin in overweight and normal weight women with PCOS.
Material and Method: Thirty-five patients normal weight women with PCOS (BMI\<25) and 38 obese women with PCOS (BMI≥25) were included in this prospective, cross-sectional study. Patients were selected according to Rotterdam criteria. Serum betatrophin levels were studied by ELISA method and then compared between these two groups besides the following additional parameters as waist circumference/hip circumference ratio, fasting blood glucose, 75 g OGTT (oral glucose tolerance test) results and HOMA-IR levels.
Comparison of the Betatrohin serum marker of insulin resistance in normal weight and overweight women with polycystic ovary syndrome cases.
-Polycystic ovary syndrome according to 2003 Rotterdam PCOS Consensus diagnostic criteria
Exclusion criteria
35 cases
Diagnostic Test: serum marker levels
38 cases
Diagnostic Test: serum marker levels
two groups comparisons
serum Betatrophin levels
ng/L
Time frame: 30 min
Waist/hip ratio
centimeter
Time frame: 5 min
75 gr OGTT(oral glucose tolerance test)
(mg/dl)
Time frame: 2 hours
BMI (body mass index)
kg/m2
Time frame: 5 minute
Plan to share: Yes — If needed
Supporting information: Study protocol, Sap, Icf, Csr, Analytic code
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hatice Akkaya